• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

    4/8/24 12:44:00 PM ET
    $DOW
    $PFE
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOW alert in real time by email

    HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

    Scott Barnum, Director of Manufacturing

    Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.

    "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer. "Their proven leadership and experience in the chemicals industry will fuel ALTIVIA's growth."

    Scott Barnum

    Mr. Barnum has 30 years of experience in the chemicals industry, including phosgenation, chlorination, sulfonation, and esterification processes. Prior to joining ALTIVIA, Mr. Barnum served as the Director of Manufacturing at Niacet Corporation, a division of Kerry Group, plc (OTC Markets KRYAY), an industry-leading manufacturer in food feed, and pharmaceutical additives. Mr. Barnum served as board member of the Buffalo Niagara Manufacturing Alliance, representing 194 member companies.

    During his career, Mr. Barnum has been recognized for his contributions to environmental, safety, and health management. Mr. Barnum holds a Bachelor of Science in Chemical Engineering from The State University of New York.

    Dean Hale

    Mr. Hale has spent the last 33 years in various engineering capacities in the chemicals industry, focused on process development, implementation, and optimization. He brings a breadth of industry experience in applications including petrochemicals, semiconductor chemicals, pharmaceuticals, and food additives. Prior to joining ALTIVIA, he most recently served as the Engineering Manager for Niacet Corporation, a division of Kerry Group, plc (OTC Markets: KRYAY), and has held various engineering and project management roles for DOW (NYSE:DOW) and Pfizer (NYSE:PFE).

    Mr. Hale has been a recipient of the Pfizer Innovation Award and the Teamwork Award, and Pharmacia's Outstanding Performance Recognition Award. Mr. Hale holds a Bachelor of Science in Chemical Engineering from Michigan State University and is certified as a Project Management Professional.

    Mr. Barnum's and Mr. Hale's leadership were instrumental in Niacet's winning the American Chemistry Council's (ACC) Company of the Year Award for outstanding environmental, safety, health, and security performance.

    About ALTIVIA

    Headquartered in Houston, Texas, privately held ALTIVIA was founded in 1986 and today operates four petrochemical and specialty chemical manufacturing facilities in Texas, Ohio, and West Virginia.

    • ALTIVIA Petrochemicals, with facilities in Haverhill, Ohio, is the third largest merchant producer of Phenol, Acetone, and alpha-methyl-styrene in the Americas.
    • ALTIVIA Specialty Chemicals, the largest producer of Phosgene derivative intermediates in the Americas, including chloroformates and acid chlorides, serving the pharmaceutical, organic peroxide, and agricultural markets from its operations in LaPorte, Texas.
    • ALTIVIA Ketones & Additives, a global leader and producer of ketones and carbinols at its facilities in Institute, West Virginia. This business was acquired from The Dow Chemical Company in 2019, and it serves the coatings, industrial and automotive lubricants, and adhesives industries.
    • ALTIVIA Oxide Chemicals specializes in custom production of various chemical intermediates serving surfactant, lubricant, and fuel additives markets. The production facility in Crosby, Texas, includes 31 reactors and distillation trains with ethoxylation, propoxylation and a range of organic reaction capabilities.

    For more information contact:

    Kelly Kimberly

    +1.713.822.7538

    [email protected] 

    Dean Hale, Corporate Engineering Manager

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/altivia-appoints-scott-barnum-as-director-of-manufacturing-and-dean-hale-as-corporate-engineering-manager-302110654.html

    SOURCE ALTIVIA

    Get the next $DOW alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DOW
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Dow Inc.
    $DOW
    7/25/2025$32.00Outperform → In-line
    Evercore ISI
    Dow Inc.
    $DOW
    6/23/2025$22.00Market Perform → Underperform
    BMO Capital Markets
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Dow Inc.
    $DOW
    4/15/2025$28.00Buy → Underperform
    BofA Securities
    Dow Inc.
    $DOW
    4/4/2025$31.00Overweight → Neutral
    Analyst
    Dow Inc.
    $DOW
    1/7/2025$60.00 → $53.00Overweight → Neutral
    Piper Sandler
    Dow Inc.
    $DOW
    12/18/2024$56.00In-line → Outperform
    Evercore ISI
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    More analyst ratings

    $DOW
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DOW
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dial Debra L. bought $26,197 worth of shares (675 units at $38.81) (SEC Form 4)

      4 - DOW INC. (0001751788) (Issuer)

      2/11/25 4:15:26 PM ET
      $DOW
      Major Chemicals
      Industrials
    • Director Banister Gaurdie E. Jr. bought $299,932 worth of shares (7,339 units at $40.87) (SEC Form 4)

      4 - DOW INC. (0001751788) (Issuer)

      12/17/24 4:59:47 PM ET
      $DOW
      Major Chemicals
      Industrials

    $DOW
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing dataDoses will be ready to sh

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older To date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing data Doses will

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits

      A study published on 29 June 2025 in international peer reviewed medical journal Expert Opinion on Drug Safety by Frey et al. has found that use of Pfizer's Depo-Provera (DMPA) for more than one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma, a type of brain tumour, compared with the use of certain combined birth control pills1.Global pharmaceutical company Pfizer Inc. (NYSE:PFE), manufacturer of Depo-Provera, is facing a multidistrict litigation (MDL No.3140) in the USA, currently comprising over 550 lawsuits against the company by women who used Depo-Provera for more than one year and developed a meningioma.The number of lawsuits has increased fr

      7/24/25 7:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DOW
    $PFE
    SEC Filings

    See more

    $DOW
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DOW
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Dow Inc.

      10-Q - DOW INC. (0001751788) (Filer)

      7/25/25 7:44:46 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Dow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DOW INC. (0001751788) (Filer)

      7/24/25 6:03:16 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Dow Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Material Impairments, Other Events

      8-K - DOW INC. (0001751788) (Filer)

      7/7/25 6:03:40 AM ET
      $DOW
      Major Chemicals
      Industrials
    • SEC Form 4 filed by Chairman & CEO Bourla Albert

      4 - PFIZER INC (0000078003) (Issuer)

      7/16/25 6:20:20 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Taraporevala Cyrus

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:39:02 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith James C

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:59 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dow downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Dow from Outperform to In-line and set a new price target of $32.00

      7/25/25 8:58:32 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Dow downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Dow from Market Perform to Underperform and set a new price target of $22.00

      6/23/25 8:03:18 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DOW
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Dow Inc.

      SC 13G/A - DOW INC. (0001751788) (Subject)

      11/12/24 2:25:16 PM ET
      $DOW
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Dow Inc.

      SC 13G/A - DOW INC. (0001751788) (Subject)

      11/4/24 11:51:32 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Dow Inc.

      SC 13G/A - DOW INC. (0001751788) (Subject)

      10/17/24 12:57:12 PM ET
      $DOW
      Major Chemicals
      Industrials

    $DOW
    $PFE
    Financials

    Live finance-specific insights

    See more
    • Dow declares quarterly dividend of 35 cents per share

      Adjusting dividend by 50% in response to prolonged industry downturnAligning payout size to ensure capital allocation flexibility and a balanced framework that enables higher returns for shareholders The Company continues to target a competitive dividend across the economic cycle MIDLAND, Mich., July 24, 2025 /PRNewswire/ -- Dow (NYSE:DOW) today announced that its Board of Directors has declared a dividend of 35 cents per share. The adjustment in payout size reflects Dow's balanced capital allocation approach and enhances financial flexibility amidst a persistently challenging macroeconomic environment.

      7/24/25 6:01:00 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Dow reports second quarter 2025 results

      MIDLAND, Mich., July 24, 2025 /PRNewswire/ -- Dow (NYSE:DOW): 2Q25 FINANCIAL HIGHLIGHTS Net sales were $10.1 billion, down 7% year-over-year, reflecting declines in all operating segments. Sequentially, net sales were down 3%, as seasonally higher demand in Performance Materials & Coatings was more than offset by declines across the other operating segments.Volume decreased 1% year-over-year, as gains in the U.S. and Canada were more than offset by declines in Europe, the Middle East, Africa and India (EMEAI). Sequentially, volume decreased 2%, as seasonally driven gains in Pe

      7/24/25 6:00:00 AM ET
      $DOW
      Major Chemicals
      Industrials
    • Pfizer Declares Third-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,

      6/25/25 5:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DOW
    $PFE
    Leadership Updates

    Live Leadership Updates

    See more
    • Dow announces results from 2025 Annual Stockholder Meeting

      Declares quarterly dividend of 70 cents per shareRichard K. Davis re-elected independent lead directorMIDLAND, Mich., April 10, 2025 /PRNewswire/ -- Dow (NYSE:DOW) is pleased to report the results of its 2025 Annual Meeting of Stockholders. Today stockholders elected Samuel R. Allen, Gaurdie E. Banister Jr., Wesley G. Bush, Richard K. Davis, Jerri DeVard, Debra L. Dial, Jeff M. Fettig, Jim Fitterling, Jacqueline C. Hinman, Rebecca B. Liebert, Luis Alberto Moreno, Jill S. Wyant, and Daniel W. Yohannes to the Company's Board of Directors for one-year terms. Stockholders approved

      4/10/25 4:15:00 PM ET
      $DOW
      Major Chemicals
      Industrials
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance